<DOC>
	<DOCNO>NCT01642212</DOCNO>
	<brief_summary>This clinical trial test experimental drug treatment Eosinophilic Esophagitis ( EoE )</brief_summary>
	<brief_title>OBS Adolescent Adults With EOE : A Phase II , Randomized , Double-Blind , Placebo Controlled , Study With Open Label Extension</brief_title>
	<detailed_description>Eosinophilic Esophagitis ( EoE ) inflammatory disorder esophagus recognize clinical entity . Symptoms include feed problem , heartburn , regurgitation , vomit , abdominal pain food impaction . The symptom EoE may similar gastroesophageal reflux disease ( GERD ) resolve gastric acid suppression . EoE define histologically presence &gt; 15 intraepithelial eosinophil per high power field one esophageal biopsy specimens . This Phase II study compare oral budesonide ( OBS ) placebo demonstrate OBS induce histologic response symptom response use Dysphagia Symptom Questionnaire 16 week course therapy .</detailed_description>
	<mesh_term>Esophagitis</mesh_term>
	<mesh_term>Eosinophilic Esophagitis</mesh_term>
	<mesh_term>Budesonide</mesh_term>
	<criteria>Males Females , age 1140 Histologic evidence EoE History clinical symptom EoE include dysphagia Willing continue dietary , environmental medical therapy Ability read understand english Written Consent Any Medical condition may compromise safety subject interfere sign symptom EoE Use immunomodulatory therapy Current use swallow corticosteroid Esophageal stricture , varix upper GI bleed Other current disease GI tract Current viral infection immunodeficiency condition Pregnancy Hypersensitivity budesonide History non compliance</criteria>
	<gender>All</gender>
	<minimum_age>11 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>EoE</keyword>
</DOC>